Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025395 | 1.00 | CNR2 (0.33) | CNR2KMT2AHTTMEN1MAPT | |
| SCHEMBL16303855 | 0.78 | S1PR1 (0.35) | KMT2AHTTMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL21179063 | 0.76 | ERN1 (0.39) | KMT2AHTTMEN1MAPTPKM | |
| SCHEMBL29337480 | 0.76 | PDXK (0.36) | KMT2AHTTMEN1MAPTPKM | |
| SCHEMBL17865351 | 0.75 | — | — | |
| SCHEMBL17865350 | 0.74 | DYRK1A (0.31) | KMT2AHTT | |
| SCHEMBL16303844 | 0.73 | MEN1 (0.36) | KMT2AHTTMEN1MAPTHSD17B10 | |
| SCHEMBL611665 | 0.69 | — | — | |
| SCHEMBL3020225 | 0.68 | MEN1 (0.41) | KMT2AHTTMEN1HSD17B10SMN1; SMN2 | |
| SCHEMBL3020221 | 0.68 | MEN1 (0.41) | KMT2AHTTMEN1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | CNR2 2242/4885KMT2A 4027/4885HTT 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.